Hisamoto K, Ohmichi M, Kanda Y, Adachi K, Nishio Y, Hayakawa J, Mabuchi S, Takahashi K, Tasaka K, Miyamoto Y, Taniguchi N, Murata Y
Department of Obstetrics and Gynecology, Osaka University Medical School, 2-2, Yamadaoka, Suita, Osaka 565-0871, Japan.
J Biol Chem. 2001 Dec 14;276(50):47642-9. doi: 10.1074/jbc.M103853200. Epub 2001 Oct 10.
Raloxifene is a tissue-selective estrogen receptor modulator. The effect of estrogen on cardiovascular disease is mainly dependent on direct actions on the vascular wall involving activation of endothelial nitric oxide synthase (eNOS) via Akt and extracellular signal-regulated protein kinase (ERK) cascades. Although raloxifene is also known to activate eNOS in the vascular endothelium, the molecular mechanism responsible for this effect remains to be elucidated. In studies of both human umbilical vein endothelial cells and simian virus 40-transformed rat lung vascular endothelial cells (TRLECs), the raloxifene analog LY117018 caused acute phosphorylation of eNOS that was unaffected by actinomycin D and was blocked by the pure estrogen receptor antagonist ICI182,780. Activation of Akt by raloxifene reached a plateau at 15-30 min and declined thereafter, a similar time frame to that of Akt activation by 17beta-estradiol. On the other hand, both activation and phosphorylation of ERK by raloxifene showed a biphasic pattern (peaks at 5 min and 1 h), whereas ERK activation and phosphorylation by 17beta-estradiol reached a plateau at 5 min and declined thereafter. A MEK inhibitor, PD98059, had no effect on the raloxifene-induced Akt activity, suggesting an absence of cross-talk between the ERK and Akt cascades. Either exogenous expression of a dominant-negative Akt or pretreatment of TRLECs with PD98059 decreased the raloxifene-induced eNOS phosphorylation. Moreover, raloxifene stimulated the activation of Akt, ERK, and eNOS in Chinese hamster ovary cells expressing estrogen receptor alpha but not Chinese hamster ovary cells expressing estrogen receptor beta. Our findings suggest that raloxifene-induced eNOS phosphorylation is mediated by estrogen receptor alpha via a nongenomic mechanism and is differentially mediated by Akt- and ERK-dependent cascades.
雷洛昔芬是一种组织选择性雌激素受体调节剂。雌激素对心血管疾病的影响主要取决于对血管壁的直接作用,涉及通过Akt和细胞外信号调节蛋白激酶(ERK)级联激活内皮型一氧化氮合酶(eNOS)。虽然已知雷洛昔芬也能激活血管内皮中的eNOS,但其产生这种作用的分子机制仍有待阐明。在人脐静脉内皮细胞和猿猴病毒40转化的大鼠肺血管内皮细胞(TRLECs)的研究中,雷洛昔芬类似物LY117018引起eNOS的急性磷酸化,放线菌素D对此无影响,而纯雌激素受体拮抗剂ICI182,780可阻断这种磷酸化。雷洛昔芬激活Akt在15 - 30分钟时达到平台期,此后下降,这与17β-雌二醇激活Akt的时间框架相似。另一方面,雷洛昔芬对ERK的激活和磷酸化呈现双相模式(在5分钟和1小时达到峰值),而17β-雌二醇对ERK的激活和磷酸化在5分钟时达到平台期,此后下降。MEK抑制剂PD98059对雷洛昔芬诱导的Akt活性没有影响,表明ERK和Akt级联之间不存在相互作用。显性负性Akt的外源性表达或用PD98059预处理TRLECs均可降低雷洛昔芬诱导的eNOS磷酸化。此外,雷洛昔芬刺激表达雌激素受体α的中国仓鼠卵巢细胞中Akt、ERK和eNOS的激活,但不刺激表达雌激素受体β的中国仓鼠卵巢细胞。我们的研究结果表明,雷洛昔芬诱导的eNOS磷酸化是由雌激素受体α通过非基因组机制介导的,并且由Akt和ERK依赖性级联差异介导。